Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIN trial. 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals Dougados, M., Kavanagh, A., Espinoza, L., Sibilia, J., Aranda, R., Becker, J. C., White, A., Genovese, M., Schiff, M., Luggen, M. WILEY-BLACKWELL. 2005: S137–S138
View details for Web of Science ID 000232207800297